Alumis Inc. (NASDAQ:ALMS) is likely one of the 10 Greatest Performing Shares of Q1 2026 to Look ahead to Q2. On March 30, Raymond James reaffirmed its Sturdy Purchase score on Alumis Inc. (NASDAQ:ALMS) with a worth goal of $46 after the corporate introduced Section 3 trial knowledge on the American Academy of Dermatology assembly.
Raymond James identified that full Section 3 knowledge was introduced for each the corporate’s envu and competitor Takeda Pharmaceutical Firm Restricted’s (NYSE:TAK) zasocitinib in adults with average to extreme plaque psoriasis.
The analysis agency famous that there’s significant differentiation in security profiles between the 2 medicine. Zasocitinib confirmed increased charges of treatment-emergent adversarial occasions, critical adversarial occasions and zits. It additionally had about twice the speed of higher respiratory tract infections and diarrhea in comparison with Alumis Inc.’s (NASDAQ:ALMS) envu. Raymond James believes envu emerged with a powerful benefit over zasocitinib.
On the identical day, Guggenheim additionally reiterated its Purchase score on Alumis Inc. (NASDAQ:ALMS) with a worth goal of $32 on the inventory after the corporate’s Section 3 psoriasis trials introduced on the 2026 American Academy of Dermatology Annual Assembly.
Alumis Inc. (NASDAQ:ALMS) is a late-stage biopharma firm centered on leveraging its proprietary knowledge analytics platform and precision method and creating next-generation focused therapies for a variety of immune-mediated ailments.
Whereas we acknowledge the potential of ALMS as an funding, we imagine sure AI shares supply higher upside potential and carry much less draw back threat. In case you’re on the lookout for a particularly undervalued AI inventory that additionally stands to profit considerably from Trump-era tariffs and the onshoring pattern, see our free report on the greatest short-term AI inventory.
READ NEXT: 10 Greatest Automobile Shares to Purchase in 2026 and 10 Greatest AI Shares to Purchase for the Subsequent 10 Years.
Disclosure: None. Observe Insider Monkey on Google Information.
